Targeting a specific enzyme to treat Alzheimer's disease
Silencing of astrocytic MAGL as a therapy for Alzheimer’s disease
['FUNDING_OTHER'] · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · NIH-10633381
This study is exploring a new way to help people with Alzheimer's by targeting a specific enzyme in brain cells to reduce inflammation, which could slow down the disease and improve thinking skills.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER (nih funded) |
| Locations | 1 site (SAN ANTONIO, UNITED STATES) |
| Trial ID | NIH-10633381 on ClinicalTrials.gov |
What this research studies
This research investigates a new approach to treating Alzheimer's disease by focusing on a specific enzyme called monoacylglycerol lipase (MAGL). The study aims to selectively inhibit MAGL in astrocytes, which are supportive cells in the brain, to reduce neuroinflammation and potentially slow the progression of Alzheimer's. By understanding how this enzyme affects the brain's inflammatory response, the research seeks to develop a targeted therapy that could improve cognitive function in patients. The methodology involves both laboratory studies and animal models to assess the effectiveness and safety of this treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults diagnosed with Alzheimer's disease or those at risk of developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel therapy that slows the progression of Alzheimer's disease and improves the quality of life for patients.
How similar studies have performed: Previous studies have shown promise in targeting MAGL for neurodegenerative diseases, indicating potential success for this approach.
Where this research is happening
SAN ANTONIO, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCIENCE CENTER — SAN ANTONIO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, CHU — UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
- Study coordinator: CHEN, CHU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia